Hydronephrosis Market

• In June 2023, Novartis AG bolstered its innovative medicines strategy and renal pipeline by acquiring Chinook Therapeutics. This acquisition may expand the company’s drug portfolio to target kidney disease treatment.

• In August 2023, Novartis announced the successful acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company headquartered in Seattle, WA. Chinook Therapeutics specializes in the research, development, and commercialization of precision medicines targeting kidney diseases.

In this report, the Hydronephrosis Market has been segmented by Treatment, Type, Diagnosis and Geography.

Hydronephrosis Market, Segmentation by Treatment

The Hydronephrosis Market has been segmented by Treatment into Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization, Steroid Therapy, and Others.

Shock Wave Lithotripsy

Shock Wave Lithotripsy (SWL) is a non-invasive treatment for hydronephrosis caused by kidney stones, covering about 35% of therapeutic approaches. Using targeted shock waves, it breaks stones into smaller pieces, reducing the need for surgery. This method ensures faster recovery and less hospitalization, making it preferred for stone-induced hydronephrosis.

Laparoscopy

Laparoscopic surgery is a minimally invasive technique used for correcting structural obstructions like ureteropelvic junction blockage. Representing nearly 25% of treatments, it uses small incisions and precise tools for enhanced surgical accuracy. Patients benefit from lower post-operative pain and shorter hospital stays, while surgeons favor it for complex or recurring cases.

Bladder Catheterization

Bladder Catheterization provides relief for hydronephrosis due to urinary retention or obstruction, accounting for around 20% of treatments. This temporary intervention ensures proper urine drainage, alleviates kidney pressure, and reduces the risk of infection or complications. It often serves as a preparatory step before more definitive procedures.

Steroid Therapy

Steroid Therapy, used in about 10% of cases, targets hydronephrosis associated with inflammation or autoimmune conditions. By reducing swelling and obstruction, steroids help maintain kidney function. They are often combined with other treatments and require careful monitoring to balance effectiveness with safety.

Others

Other treatment options, representing approximately 10% of interventions, include ureteral stenting, nephrostomy, and alternative surgeries. These methods are typically reserved for emergency cases or when standard therapies fail. They aim to restore normal urine flow, relieve kidney pressure, and prevent long-term complications.

Hydronephrosis Market, Segmentation by Diagnosis Method

The Hydronephrosis Market has been segmented by Diagnosis into Ultrasound, CT Scan, MRI, X-ray, and Urodynamics.

Ultrasound

Ultrasound is the most widely used diagnostic tool for hydronephrosis, accounting for about 40% of all diagnostic procedures. It is non-invasive, safe, and cost-effective, making it the first choice for initial assessment. Ultrasound can accurately detect kidney swelling and obstruction, providing real-time imaging without radiation exposure. Its portability and ease of use make it ideal for pediatric and prenatal screening.

CT Scan

CT Scan offers highly detailed imaging and is particularly effective for identifying urinary tract obstructions and stones. Representing approximately 25% of diagnostics, it is preferred when ultrasound results are inconclusive. CT scans provide a comprehensive view of kidney anatomy and surrounding structures, helping clinicians plan interventions with greater precision. The technique is valued for its accuracy and reliability in complex cases.

MRI

MRI (Magnetic Resonance Imaging) accounts for roughly 15% of hydronephrosis diagnostic procedures. It is ideal for patients needing detailed soft tissue imaging without exposure to ionizing radiation. MRI is especially useful in evaluating congenital anomalies and structural abnormalities in the kidneys and urinary tract. Though less common than ultrasound or CT, it provides high-resolution images crucial for surgical planning.

X-ray

X-ray imaging is a traditional method used in about 10% of hydronephrosis diagnosis cases. It is typically combined with contrast studies like intravenous pyelogram (IVP) to visualize urinary tract blockages. X-rays are quick and accessible, making them useful for preliminary assessment or emergency situations. However, they are gradually being replaced by more advanced imaging techniques for detailed evaluation.

Urodynamics

Urodynamics testing, representing roughly 10% of diagnostic approaches, measures bladder function and urine flow dynamics. It is especially valuable in diagnosing functional obstructions that do not show structural changes. The procedure helps physicians determine treatment strategies by analyzing how the bladder and urethra perform under various conditions. It is often used in complex or recurrent cases of hydronephrosis.

Hydronephrosis Market, Segmentation by Type

The Hydronephrosis Market has been segmented by Type into Unilateral Hydronephrosis and Bilateral Hydronephrosis.

Unilateral Hydronephrosis

Unilateral Hydronephrosis, which impacts only one kidney, accounts for around 65% of all hydronephrosis cases. Common causes include kidney stones, ureteral blockage, or congenital anomalies on one side. Timely diagnosis with imaging techniques allows for focused treatment, reducing the risk of long-term kidney damage. Key symptoms often include flank pain, urinary infections, or blood in the urine.

Bilateral Hydronephrosis

Bilateral Hydronephrosis affects both kidneys and represents about 35% of cases. It is generally more serious because urinary obstruction affects both kidneys simultaneously. Early identification is critical to prevent kidney failure or chronic renal issues. Symptoms can include swelling, reduced urine output, and systemic complications, making rapid intervention essential.

Hydronephrosis Market, Segmentation by Geography

In this report, the Hydronephrosis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Hydronephrosis Market Share (%), by Geographical Region

North America

North America dominates the hydronephrosis market. It contributes approximately 35% of global revenue. The region benefits from advanced healthcare facilities. High prevalence of urinary disorders and increasing adoption of minimally invasive procedures are key growth drivers. Innovations in diagnostic imaging and growing patient awareness further boost market growth.

Europe

Europe accounts for around 25% of the global hydronephrosis market. Growth is driven by specialized medical centers and an expanding aging population. Countries like Germany, the UK, and France lead in cutting-edge surgical treatments. Rising awareness and access to advanced healthcare services support market expansion. The adoption of modern diagnostic technologies is also increasing.

Asia Pacific

Asia Pacific contributes nearly 20% to the global hydronephrosis market. Rapid development of healthcare infrastructure and large patient populations are fueling growth. Increasing focus on kidney health awareness and higher demand for non-invasive treatments drive market expansion. Nations like China, India, and Japan are key growth hubs in the region.

Middle East and Africa

Middle East and Africa account for roughly 10% of the global market. Growth is supported by investments in healthcare and improved diagnostic capabilities. Rising prevalence of urinary tract disorders and gradual adoption of advanced treatment techniques drive demand. Medical device usage is increasing across the region as infrastructure improves.

Latin America

Latin America contributes about 10% to the global hydronephrosis market. Growth is driven by rising awareness of kidney health and improvements in healthcare access. Increasing use of modern diagnostic and treatment approaches and Brazil and Mexico emerging as leading markets support expansion. The significant patient population continues to influence market dynamics.

This report provides an in depth analysis of various factors that impact the dynamics of Global Hydronephrosis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Hydronephrosis Market include:

• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• Baxter International Inc.
• Olympus Corporation
• KARL STORZ SE & Co. KG
• B. Braun Melsungen AG
• Stryker Corporation
• Coloplast Group
• Teleflex Incorporated

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis